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Overview
This lecture is divided into three parts:
A review of the space environment.
Current and future research on immune and
microbial aspects of space flight.
A practical guide to current operational
practice.
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Introduction
Slightly more than 500 people have flown in space, most of
them for short periods of time. The total number of person-
years in space is small. Given this fact, and given rigorous
astronaut screening, it is not surprising that the accumulated
infectious disease experience in space is also small, and
mostly, theoretical. As the human space presence expands,
we may expect mission length, total accumulated person-
years and the environmental complexity to increase. Add to
the mix both changes in human immunity and microbial
virulence, and it becomes realistic to consider infectious
scenarios and the means to mitigate them
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Introduction
• This lecture will cover the inhabited space environment from
the perspective of host-microbe interactions, current relevant
research, and the current countermeasures used. Future
challenges will be discussed and there will be opportunity to
ask questions about Space Operations. The audience is
encouraged to think about what medical tools you would
choose to have in different types of mission, what you would
be willing to leave behind, and how you would compensate
for the necessary trade offs in mission design.
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Thought Provocation I
Has anyone ever had pneumonia in space? No.
Could we treat pneumonia in space? Yes, with limitations.
Do the following items change in Space?
• Pulmonary blood flow? Yes
• Human immunity? Yes.
• Aerosol droplet trajectory? Yes
• Microbial virulence? Sometimes
• Antibiotic pharmacokinetics? Unknown
• So is pneumonia management in Space going to be routine? No.
Liven a lunar base with1,000 people, will somebody sooner or later get
pneumonia? Does lunar dust exposure increase the risk? What terrestrial
industries have similar particulate exposures? Will you be treating on the
moon or evacuating?
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The take-away message:
Space infectious processes and their
management will be for the most part familiar
entities, but with the potential for variable
presentations based on factors that manifest in
the space environment.
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• During the return of Apollo XIII to Earth approximately 4
days into the aborted mission, one crewmember developed a
urinary tract infection during an interval of restricted water
intake and dehydration. The mission was brief, but very
stressful. We do not have insight into the crewmember’s
transient immune state. Effective treatment was not achieved
in flight prior to landing.
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Thought Provocation II
If extremity cellulitis is more aggressive and
persistent in patients with a history of lymph
node resection, how would extremity fluid
shifts in Space affect the natural history of
cellulitis on orbit? In the event of cellulitis in
Space, which clinical experience and which
patient categories should we draw upon in
assessing risk and managing the illness?
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Short Case
• At an unspecified time in the past few years, you are asked
about a man in excellent health with abrupt-onset skin lesions
on his leg.
• He noticed the lesions upon awakening from sleep in Florida,
where he was staying in work-related temporary lodging in
quarantine.
• The lesions were initially flat, firm, and mildly pruritic, with no
streaking or induration. He otherwise felt well, and was
looking forward to launching into space in 36 hours when he
followed his customary practice and went swimming in the
warm waters off of a Florida beach.
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Case 1 continued...
• After a refreshing swim, during which he
experienced no trauma and noticed no
unusual marine organisms, he found that
the pruritis has intensified. 24 hours
before launch, his leg has the following
appearance:
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Case 1 continued
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Case I Differential
1. Mosquito bite, sterile vs. super-infected
2. Bedbug, fire ant, brown recluse spider
3. Vibrio vulnificus, other gram-negatives
4. CA -MRSA (+/- P VL)
5. Marine organism envenomation
6. Contact allergy from neomycin
7. Contact allergy from nickel-containing
electrode
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Case 1 considerations
• The health of the patient and the other crewmembers, and mission
success are all critical. When risk hard to quantify, risk perception varies
with the individual. NASA mostly a non-medical culture.
• Limited hands-on follow-up anticipated
• While there is limited medical capacity aboard Shuttle, serious
complications could interrupt EVA schedule, or even require de-orbit.
Iatrogenic complications, including allergic reaction or C. difficile colitis
could themselves jeopardize Crew, EVA timeline and Mission.
• In theory, you could delay the launch. Shuttle Crews do not normally
have back-ups to replace individuals close to launch.
• A definitive course of action is desired, you have 24 hours, what’s next?
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Case 1 options: Pick One
1. Do nothing, except cover lesions during launch and EVA
2. Topical steroids alone
3. Topical steroids/antibiotic mixture (no time to spare!)
4. Topical antibiotics alone
5. Oral antibiotics during mission (and launch with a supply of
oral vancomycin as precaution against C. difficile)
6. Remove the offending agent and observe
7. Debridement and hospitalization
8. Diagnostic testing, treat in Space after launch based on
results
9. Delay the mission and observe
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Case 1 continued
• After some debate, the decision is reached to
spend the next 12 hours using topical steroids,
alone. This in fact was successful, with
resolution of the pruritis and non -progression
of the lesions in the day before launch.
• Use of antibiotics in parallel to steroids was
specifically rejected.
• Why ?
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Case 1 conclusion
In this case, the patient was not “sick,” mosquito bite
was considered most likely, with a good chance of
demonstrable improvement before launch. Had
antibiotics been used, it would have blurred the cause
of the improvement, and would have prompted further
use of antibiotics on orbit, at some risk. Had steroids
alone failed, the antibiotic option remained before and
after launch. The non-toxic appearance and failure to
progress argued against the more dangerous items on
the differential. The Crewmember did well and
performed all scheduled tasks in a successful mission.
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How is Case 1 typical of Space Medicine?
Basically healthy population.
Terrestrial organisms transferred into space, possibility of altered natural
history due to some feature of space work environment.
Common problems have potential for high-stakes impact.
Risks are reduced, but cannot be taken to zero. Do no harm.
No problem is truly “common.” The total Space corporate experience of any
condition is either limited or theoretical, and the natural history cannot be
assumed to be the same as that on Earth, for reasons to be further discussed.
Timelines are tight, personnel not easily interchangeable.
Patients are remote. Access, examination, diagnostics and treatment all
severely constrained. Orbit up-mass costs $5,000 - $10,000 per pound, also
constrained by competing mass/volume/power requirements. Emergency
de-orbit for medical care is complex and is best obviated by preventing
emergency in first place.
Consultation is readily available, implementation, difficult.
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Infection is an Ecological
Phenomenon
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Space ecology
As a practical matter, the term “Space
environment” is used in this lecture to refer to
the inhabitable space environment. So, under
near-terrestrial conditions, terrestrial hosts and
microbes, themselves subtly changed, interact.
Instead of being challenged by the exotic, we
will be challenged by variations on the
familiar.
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So, from an infectious perspective,
how does the space ecological
“tripod” differ?
1. Physical environment - .
2. Host (human physiology)
3. Microbes
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Physical environment
• “Shirtsleeve” environment. Temperature, gas mix,
pressure typical of sea level office space.
• Dry. Humidity run 30-50%
– Sweat forms layers when excessive
– Water may absorb into hydrophilic surfaces
– Water forms spheres and has the potential to form “ponds”
• Radiation slightly higher than earth, but not dramatic.
• Air convection and mixing does not occur unless
driven. Fans and HEPA filters are used.
– CO2 pockets
– Droplets, flakes do not fall down
Haddon-Sep 2009
	
UNCLASSIFIED	 23
Space Environment II
• There is plenty of gravity at the orbital altitude
of the ISS (after all, the Moon doesn’t just
float away). So, “microgravity” is a term of
convenience.
• Objects in orbit are falling freely within a
gravitational field.
• The distinction between true microgravity and
free-fall is important when modeling the forces
upon organisms
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Space Environment III
• No crowds. Crewmembers arrive in small
batches, generally pre-exposed to each other
and quarantined.
• No reservoirs or vectors.
• No large-scale organics: no soil, vegetation, or
large bodies of water
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ISS Air
ISS air is sampled using impeller
samplers and is normally assessed for
total colony counts. Samples for
speciation have been obtained
periodically and the results are shown
on the following slide:
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Bacteria in ISS air by species
Acinetobacter calcoaceticus
Acinetobacter lwoffii
Acinetobacter species
Alcaligenes xylosoxidans
Bacillus licheniformis
Bacillus thuringiensis
Bacillus species
Bacillus subtilis
Corynebacterium afermemtans
Corynebacterium riegelii
Corynebacterium species
Enterobacter aerogenes
Kocuria varians (formerly Micrococcus)
Micrococcus species
Non-viable organism
Paenibacillus amylolyticus
Paenibacillus glucanolyticus
Staphylococcus aureus
Staphylococcus auricularis
Staphylococcus capitis
Staphylococcus cohnii
Staphylococcus epidermidis
Staphylococcus haemolyticus
Staphylococcus hominis
Staphylococcus lugdunensis
Staphylococcus pumilis
Staphylococcus saprophyticus
Staphylococcus simulans
Staphylococcus species
Staphylococcus vitulinus
Staphylococcus warneri
Staphylococcus xylosis
Streptococcus species
Stenotrophomonas maltophilia
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Fungi in ISS air by species
Fungi
Aspergillus flavus
Aspergillus nidulans
Aspergillus species
Aspergillus versicolor
Cladosporium species
Penicillium aurantiogriseum
Penicillium expansum
Penicillium species
Phoma species
Rhodotorula species
Scopulariopsis species
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In-Flight Fungal Levels in ISS Cabin Air
Using U.S. and Russian Hardware
• Samples Below Acceptability Limit (n=284) 	
ISS MORD acceptability limit = 100 CFU/m 3
• Samples At or Exceeding Acceptability Limit (n=9)
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Water
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Water supplies in Space
• Water on Space Shuttle stored with dissolved Iodine, which is removed prior
to use.
• Russian water on ISS is delivered municipal water treated on ISS with silver,
potable water dispensed post a heating step. Filtering step in work.
• American water delivered and stored in 44 liter bags. Also recovered from
condensate. Uses heat step for sterilization. Iodine not present in ISS water(could form precipitate with silver).
• Water in cooling loops contains Ortho-phthalaldehyde (OPA), to prevent
bacterial matting and valve malfuntion. Cooling loops do not interact with
consumable water supplies.
• Urine now recycled in US systems using acid pre-treat and heat step
• Human waste containerized and disposed on Progress module in
atmosphere
• Potential exists for condensate collection. More of a problem on Mir, with
small “ponds” forming behind panels. Shell heaters reduce likelihood.
• Water is split electrically by both US and Russian systems yielding Oxygen.
Hydrogen is vented to space
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Water testing
• Colorimetric assay for coliforms performed
periodically on potable water. None detected
to date. Means for speciation not available if
detected.
• Quantitative assay performed for cell counts
only. Recent elevations in colony counts led to
the detection of Wautersia sp. in potable water
plumbing. High resistance to silver.
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Significance of Wautersia in ISS
• Although not dangerous, is not supposed to be
present at all. Ubiquitous in terrestrial water.
Commonly found in plumbed water supplies, bottled
water, swimming pools.
• Origin terrestrial, but precise path to ISS and route of
spread in ISS plumbing hard to track even after
extensive evaluation. Evaluation slowed by
infrequent sample transport opportunities, relative
lack of microbiological assets on board.
• Demonstrates principle that generic numerical
thresholds for bacterial colony counts serve at best as
a marker. Actual hazard will vary with species.
• Ecological niches tend to get filled. Microbes may
move “under the radar” en route to niches.
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Food
• Food: generally processed terrestrial,
occasionally fresh fruit.
• Food is tested for bacteria periodically.
• Commercial food supply chain issues poses
theoretical hazard in the event contaminated
food got to orbit.
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Host Changes in Space
Cephalad fluid shifts as venous elasticity persists in absence of
high fluid column—facial edema, sinus congestion.
Axial loading forces gone—muscle mass drops in absence of
replacement exercise. Bone mass drops in part due to
persistence of normal remodeling in response to “new” load.
Calcium excretion rises from bone loss. Risk of kidney (and
therefore of obstructive UTI) rises.
Drug effects—early in flight space adaptation sickness is treated
with phenergan with potential for urinary retention.
Sleep cycle disruption with possible effect on immunity.
Lung perfusion zones blend together
Normal flora remain normal humans are a mobile environment
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Normal flora example:
Does Staph go into Space?
Yes. It has been found on the ISS. Individual
strains have been tracked from date of arrival
across more than one expedition. This was not
associated with disease. Antibiograms were
obtained, there was no sign of MRSA.
V.A. Castro, A.N. Thrasher, M. Healy, C.M. Ott,and D.L. Pierson. 2003.
Microbial Characterization During the Early Habitation of the International
Space Station. Microbial Ecology 47: 119-126.
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CA-MRSA risk
The eventual appearance of CA-MRSA in Space
seems plausible, given three assumptions:
(A) Staph goes to Space (already shown)
(B) CA-MRSA is spreading on Earth
(C) Space isolates reflect a sampling of the
“action on the ground”
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CA-MRSA Exercise
• Short of not launching anybody, what reasonable
precautions could be taken to prevent launching CA-
MRSA into space?
• What degree of (un)certainty is acceptable?
• Objectively, how bad might the consequences be, and
what is most likely?
• Under what circumstances would you allow it?
• What on-orbit resources should be available in the
event CA-MRSA successfully reaches orbit?
• Do potential changes in host immunity undermine the
usefulness or reliability of predictions and planning?
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Crucian, et al., space immunity
• “In-flight testing of humans has revealed that latent herpes viruses
reactivate to a high level during short-duration spaceflight, but it is
currently unknown whether this phenomenon would persist or intensify
during extended duration flight, or eventually resolve itself. During long
duration flight, cell-mediated immunity has been demonstrated to be
reduced in some subjects, and there may be a relationship between the
observed in-flight immune changes and reactivation of latent viruses.
Postflight human testing has revealed severely depressed T cell function
following 6 months of flight, but unaltered function following short-
duration flight. Altered cytokine production patterns and potentially a shift
to the Th2 pattern have been observed following spaceflight. Natural killer
(NK) cell, monocyte, and neutrophil function have all been found to be
reduced following spaceflight. Stress hormone levels have been found to
be elevated following flight, heavily dependent on mission duration.
Various animal studies have demonstrated similar findings either during or
after flight.”
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Immune System in Space
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Pierson, et al, Viral re-activation
• Stress-induced subclinical reactivation of
varicella zoster virus in astronauts. J Med
Virol 2004;72; 174-9
• Varicella Zoster in the Saliva of Patients with
Herpes zoster JID 2008:197 (1 March)
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Microbe changes in space
• Normal flora travel with us.
• Intuitively, one might reason that a microbe
would not change in space. How would it
“tell” where it was? There is no fluid column
to speak of, nor a vestibular system. No
reason to think that evolution has produced
an organelle that detects orbital velocity or a
subtle change in the curve of space.
• But that turns out not to be the point...
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Microbe Changes in Space
• Shear forces are altered in free-fall, and
bacteria have had in their history opportunity
to experience environments with variable shear
forces. So the effect of orbital free-fall is to
bring out one mode of terrestrial response.
Even within a host, shear forces vary by region
and tissue. Such as between brush border
microvilli.
• CA Nickerson, JW Wilson, CM Ott, PNAS Oct 9, 2007, vol. 104 no. 41 16299-16304
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When you hear
hoofbeats...
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Horses, Quaggas and Zebras
Given what we know about genomes,
are you completely sure that horses
don’t carry genes for stripes?
That which looks new, may in fact be
old, and may remain in play under
certain conditions.
Haddon-Sep 2009
	
UNCLASSIFIED	 50
Nickerson, Ott, Wilson, et al
• “Space flight alters bacterial gene
expression and virulence and reveals
a role for global regulator Hfq”
• PNAS October 9, 2007, Vol. 104, no.
41 16299-16304
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Space flight initially modeled with a rotating wall
vessel (R WV) that allows bacterial cultures to grow
with a minimum of shear forces.
“ Specifically, S(almonella) typhimurium grown
in ... low-shear modeled microgravity (LSMMG)
exhibited increased virulence, increased resistance to
environmental stresses (acid, osmotic and thermal),
increased survival in macrophages, and global
changes in gene expression at the transcriptional and
translational levels.”
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The experiment was repeated aboard STS-115
using a carefully structured Fluid Processing ..
Apparatus while parallel cultures obtained on
the ground. Results consistent with previous
studies using Rotating Wall Vessel. -
“The space flight environment imparts a signal
that can induce molecular changes in bcterial
cells. Furthermore, these results also provide
direct evidence that this signal can alter the
virulence of a microbial pathogen.”
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Significant differences in space -grown
Salmonella
167 genes differently expressed (+/- 2x
expression)
73 proteins at different levels
Decreased LD50 in mice, lower rate of
survival and earlier death
Extracellular material expression consistent
with biofilm.
Nickerson, Wilson, Ott, et.al PNAS 104;41;16299-16304
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Meet the new bug,
Same as the old bug
• The changes in behavior and virulence seen in Salmonella
typhimurium are widespread and reproducible.
• This is not what a mutating organism would be expected to
show, with variable changes in individual genes.
• Rather, the bacterium, placed in a novel environment, is
consistently expressing a pre-existing package, one that is
appropriate for normal low-shear environments to which the
bacterium is well adapted.
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Space Changes Suggest a New
Target for Terrestrial Therapy
• A two-fold change in Salmonella virulence
does not change the fact that you didn’t want
to be ingesting Salmonella in Space one way
or the other.
• The point is that these changes may occur in
terrestrial contexts, such as with the formation
of biofilms, and provide an opportunity to
interrupt virulence mechanisms in normal
settings.
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Effects of the Space Environment on
terrestrial microbes
• How common and how extensive?
• What are the likely mechanisms of the
observed changes?
• What is the operational relevance? What if
nobody actually gets sick?
• Should changes be made accordingly in pre-
launch screening and eradication efforts, in the
orbital pharmacy, or in orbital environmental
assays?
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Infection Control:
Longitudinal View, preflight
• Healthy crew: MED Vol A, condition at
selection
• MED Vol B condition at mission assignment
• Specific immunity to and/or demonstrated
absence of pathogens and/or absence of overt
disease.
• Prophylactic treatment and/or vaccination
• Quarantine pre-launch.
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Specific Entities Screened
MED Vol A: Syphilis (VDRL or RPR), HIV, Hepatitis
A,B,C, H. pylori (Urea breath test, serology, or
biopsy), TB (skin test, quantiferon), MRSA (nasal
cultures only).
Other disqualifying entities: General mission-impacting,
TB w/in last 2 years, LTBI untreated, malaria, AIDS,
chronic hepatitis B,C, Lyme disease, MRSA carrier
state, mission-impacting herpes simplex I, II,
intestinal parasites, herpes zoster, active or post-
herpetic neuralgia.
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MED Vol B: Timing and Wrinkles
• H. pylori. Testing at L-365/330. May use
serology, UBT, stool serology or biopsy. If
positive, treat and re-assess with UBT or Stool
antigen. Persistent positives assessed on case-
by-case basis.
• Wrinkle: Detection or conversion close to
launch, otherwise without symptoms.
• ALARA philosophy
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MED Vol B: Timing and Wrinkles
• Tuberculosis: some international variation in
screening for LTBI. MED Vol A, B protocols
include Quantiferon as means of reconciling
protocols of several different nations. Timing:
L-365/330
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MED Vol B: Timing and Wrinkles
• MRSA Nasal cultures at L-45/30 days with topical
mupirocin and anti-staphylococcal washes for 5 days.
No follow-up culture mandated, intentionally. Aim is
ALARA, recognizing that other risks emerge from
removing asymptomatic crew close to launch. If
symptomatic, a different rule is invoked.
• Wrinkle #1: Nasal swabs miss 25% of carriage
• Wrinkle #2: Potential exists for onset of carriage
between L-30 and launch, especially as all contacts
(1000’s) in that period not screened.
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Infection Control: - .
Preflight confounders
Colonists and “normal flora” can become
pathogens—risk not zero
True pathogens may have low risk that cannot be
reduced to zero
Over-aggressive preventive interventions may
cause harm or exclude valuable personnel
Risk assessment, “risk trough”
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In-Flight Infectious Safeguards
• Skin care and preservation of skin barrier (harness fit,
etc).
• Normalized exercise, sleep and nutrition
• Air filtration
• Food and Water processing (heating and biocides)
• Environmental microbial sampling
• Vaccination pre-flight may prevent secondary cases
in flight, e.g., varicella pneumonia less likely upon
exposure to another crewmember with dermatomal
zoster.
Haddon-Sep 2009
	
UNCLASSIFIED	 66
In-Flight Infectious Safeguards
• To what extent is immunity compromised?
• How much of that compromise is relevant in
the space working environment?
• To what extent can immunity be normalized?
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In-Flight Infectious Safeguards
• Pharmacological agents fall into two
categories:
• 1) Definitive treatment or suppression on
orbit, without significant disruption of mission.
Most of the topical and oral medications fall
into this category
• 2) Temporizing treatment of more serious
illnesses while evacuating to definitive care
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Antibiotics on ISS
Antivirals
Topical:
Acyclovir ointment (Zovirax) 15 gm tube (1)
Oral:
Oseltamivir (tamiflu) 75 mg tablet (30)
Valacyclovir (valtrex) 1 gm tablet (21)
Haddon-Sep 2009
	 UNCLASSIFIED	 69
Antibiotics on ISS
• Parenteral antibacterial
Amikacin 250 mg/ml (2 ml unit) (4)
Ceftriaxone (1 gm) provided with xylocaine 1% (1)
In either case, essentially a one day supply.
Haddon-Sep 2009
	 UNCLASSIFIED	 70
Antibiotics on ISS
• Oral antibacterial
Amoxicillin 500 mg tabs (84)
Azithromycin 250 mg tabs (20)
Bismuth subsalicylate tabs (48) (H. pylorii)
Cefadroxil (duricef) 500 mg capsules (40)
Levofloxacin (levaquin) 500 mg tablet (30)
Metronidazole (flagyl) 250 mg (28 tabs)
Trimethoprim/Sulfamethoxazole 160/800 mg (56)
Vancomycin 250 mg capsule (4)
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Antibiotics on ISS
• Topical Antibacterial
Bacitracin ointment 28 gm tube (1)
Ciprofloxacin Ophthalmic ointment 0.3% 3.5 gm tube (2)
Ciprofloxacin ophthalmic solution 0.3% 5 ml bottle (6)
Mupirocin ointment 2% 22 gm tube (1)
Polymyxin/Bacitracin ointment 28.3 gm tube (2)
Polymyxin B sulfate and Trimethoprim ophthalmic solution 10
ml (1)
Silver sulfadiazine cream 1% (20 gram tube) (2)
Tobramycin ophthalmic solution 0.3% 5 ml bottle (1)
Tobramycin/dexamethasone ophthalmic solution 5 ml (1)
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Antibiotics on ISS
• Oral antifungal
• Fluconazole tablets 150 mg (3)
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Antibiotics on ISS
• Topical anti-fungal
Clotrimazole cream (lotrimin) 12 gm tube (2)
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Antiseptics on ISS
• Isopropyl alcohol pads (35)
• Benzalkonium chloride wipes (58)
• Povidone iodine (betadine) swabs (15)
• Wound care items (including steri-strips and
staples as well as sutures), barriers, dressings,
drapes, oto-wicks, waste disposal bags.
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“Mir cat”
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